Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
DARA Biosciences Inc. (NASDAQ: DARA) shares surged 23.11 percent to close at $3.09 a share Tuesday. The stock traded between $3.04 and $3.55 on volume 7.38 million shares traded. The company announced that KRN5500 has received Orphan Drug Designation from the U.S. Food and Drug Administration. Shares of DARA Biosciences are up approximately 15.0 percent year-to-date.
Get more information on DARA Biosciences free access to the in-depth equity report at: www.FiveStarEquities.com/DARA
ImmunoCellular Therapeutics Ltd. (NYSEMKT: IMUC) shares spiked 14.05 percent to close at $1.38 a share Tuesday. The stock traded between $1.35 and $1.52 on volume of 9.0 million shares traded. The company announced that ICT-107 has received the orphan drug designation from the European Medicines Agency. Shares of ImmunoCellular are up approximately 50.0 percent year-to-date.
Get more information on ImmunoCellular and free access to the in-depth equity report at: www.FiveStarEquities.com/IMUC
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 15.52 percent to close at $16.15 a share Tuesday. The stock traded between $14.02 and $16.70 on volume 2.15 million shares traded. The company reported a net loss of $32.9 million, or $0.68 per share, for the fourth quarter of 2013, down from a loss of $47.0 million, or $1.15 per share, a year ago. Shares of Infinity Pharmaceuticals are up approximately 16.0 percent year-to-date.
Get more information on Infinity Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/INFI
InterMune Inc. (NASDAQ: ITMN) shares skyrocketed 170.77 percent to close at $37.80 a share Tuesday. The stock traded between $30.20 and $38.73 on volume of 50.19 million shares traded. The company announced that Esbriet, a lung disease treatment, met both the primary and secondary endpoints in the recent ASCEND study. Shares of InterMune are up approximately 155.0 percent year-to-date.
Get more information on InterMune and free access to the in-depth equity report at: www.FiveStarEquities.com/ITMN
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]